325 related articles for article (PubMed ID: 23197693)
1. Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.
Sato A; Sunayama J; Okada M; Watanabe E; Seino S; Shibuya K; Suzuki K; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cells Transl Med; 2012 Nov; 1(11):811-24. PubMed ID: 23197693
[TBL] [Abstract][Full Text] [Related]
2. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells.
Sato A; Okada M; Shibuya K; Watanabe E; Seino S; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cell Res; 2014 Jan; 12(1):119-31. PubMed ID: 24185179
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma stem cells: a new target for metformin and arsenic trioxide.
Carmignani M; Volpe AR; Aldea M; Soritau O; Irimie A; Florian IS; Tomuleasa C; Baritchii A; Petrushev B; Crisan G; Valle G
J Biol Regul Homeost Agents; 2014; 28(1):1-15. PubMed ID: 24750786
[TBL] [Abstract][Full Text] [Related]
4. Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z; Zhao G; Xie G; Zhao L; Chen Y; Yu H; Zhang Z; Li C; Li Y
Oncotarget; 2015 Oct; 6(32):32930-43. PubMed ID: 26431379
[TBL] [Abstract][Full Text] [Related]
5. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
Leidgens V; Proske J; Rauer L; Moeckel S; Renner K; Bogdahn U; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
Oncotarget; 2017 Jan; 8(5):8250-8263. PubMed ID: 28030813
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop.
An Y; Wang B; Wang X; Dong G; Jia J; Yang Q
Cell Death Dis; 2020 Feb; 11(2):115. PubMed ID: 32051395
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells.
Sato A; Okada M; Shibuya K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Kayama T; Kitanaka C
Stem Cell Res; 2013 Jul; 11(1):601-10. PubMed ID: 23651583
[TBL] [Abstract][Full Text] [Related]
8. Targeting Folate Metabolism Is Selectively Cytotoxic to Glioma Stem Cells and Effectively Cooperates with Differentiation Therapy to Eliminate Tumor-Initiating Cells in Glioma Xenografts.
Okada M; Suzuki S; Togashi K; Sugai A; Yamamoto M; Kitanaka C
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769063
[TBL] [Abstract][Full Text] [Related]
9. Metformin Attenuates ROS
Hartwig J; Loebel M; Steiner S; Bauer S; Karadeniz Z; Roeger C; Skurk C; Scheibenbogen C; Sotzny F
Front Immunol; 2021; 12():581799. PubMed ID: 33953705
[TBL] [Abstract][Full Text] [Related]
10. Targeting JNK for therapeutic depletion of stem-like glioblastoma cells.
Matsuda K; Sato A; Okada M; Shibuya K; Seino S; Suzuki K; Watanabe E; Narita Y; Shibui S; Kayama T; Kitanaka C
Sci Rep; 2012; 2():516. PubMed ID: 22816039
[TBL] [Abstract][Full Text] [Related]
11. Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.
Würth R; Pattarozzi A; Gatti M; Bajetto A; Corsaro A; Parodi A; Sirito R; Massollo M; Marini C; Zona G; Fenoglio D; Sambuceti G; Filaci G; Daga A; Barbieri F; Florio T
Cell Cycle; 2013 Jan; 12(1):145-56. PubMed ID: 23255107
[TBL] [Abstract][Full Text] [Related]
12. Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation.
Hu T; Chung YM; Guan M; Ma M; Ma J; Berek JS; Hu MC
Sci Rep; 2014 Jul; 4():5810. PubMed ID: 25056111
[TBL] [Abstract][Full Text] [Related]
13. FoxO3a functions as a key integrator of cellular signals that control glioblastoma stem-like cell differentiation and tumorigenicity.
Sunayama J; Sato A; Matsuda K; Tachibana K; Watanabe E; Seino S; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Stem Cells; 2011 Sep; 29(9):1327-37. PubMed ID: 21793107
[TBL] [Abstract][Full Text] [Related]
14. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma.
Jiang W; Finniss S; Cazacu S; Xiang C; Brodie Z; Mikkelsen T; Poisson L; Shackelford DB; Brodie C
Oncotarget; 2016 Aug; 7(35):56456-56470. PubMed ID: 27486821
[TBL] [Abstract][Full Text] [Related]
15. Isogambogenic Acid Inhibits the Growth of Glioma Through Activation of the AMPK-mTOR Pathway.
Zhao W; Peng F; Shu M; Liu H; Hou X; Wang X; Ye J; Zhao B; Wang K; Zhong C; Xue L; Gao M; Liu Y; Zhao S
Cell Physiol Biochem; 2017; 44(4):1381-1395. PubMed ID: 29186708
[TBL] [Abstract][Full Text] [Related]
16. Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?
Kast RE; Karpel-Massler G; Halatsch ME
Br J Pharmacol; 2011 Nov; 164(5):1393-6. PubMed ID: 21410456
[TBL] [Abstract][Full Text] [Related]
17. Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells.
Li Y; Wang W; Wang F; Wu Q; Li W; Zhong X; Tian K; Zeng T; Gao L; Liu Y; Li S; Jiang X; Du G; Zhou Y
J Mol Cell Biol; 2017 Aug; 9(4):302-314. PubMed ID: 28486630
[TBL] [Abstract][Full Text] [Related]
18. Glioma-associated cancer-initiating cells induce immunosuppression.
Wei J; Barr J; Kong LY; Wang Y; Wu A; Sharma AK; Gumin J; Henry V; Colman H; Sawaya R; Lang FF; Heimberger AB
Clin Cancer Res; 2010 Jan; 16(2):461-73. PubMed ID: 20068105
[TBL] [Abstract][Full Text] [Related]
19. The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?
Bonini MG; Gantner BN
IUBMB Life; 2013 Nov; 65(11):889-96. PubMed ID: 24265196
[TBL] [Abstract][Full Text] [Related]
20. Two-step activation of FOXO3 by AMPK generates a coherent feed-forward loop determining excitotoxic cell fate.
Davila D; Connolly NM; Bonner H; Weisová P; Dussmann H; Concannon CG; Huber HJ; Prehn JH
Cell Death Differ; 2012 Oct; 19(10):1677-88. PubMed ID: 22539004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
